公开(公告)号：US11963999B2

公开(公告)日：2024-04-23

申请号：US16407813

申请日：2019-05-09

Applicant: Novartis AG

Inventor： John Louis Diener ,  Jiaping Gao ,  Rick Jerome Schiebinger

IPC: A61K38/18 ,  C07K14/50

CPC classification number: A61K38/1825 ,  C07K14/50 ,  C07K2319/30

Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.